頁籤選單縮合
題名 | 三陰性乳癌臨床試驗概況淺談=Clinical Trials for Triple-negative Breast Cancer: Recent Results |
---|---|
作者 | 林欣哲; 張震鴻; 方逸萍; Lin, Hsin-che; Chang, Chen-hung; Fang, Yi-ping; |
期刊 | 藥學雜誌 |
出版日期 | 20170900 |
卷期 | 33:3=132 2017.09[民106.09] |
頁次 | 頁149-154 |
分類號 | 416.226 |
語文 | chi |
關鍵詞 | 三陰性乳癌; 臨床試驗; 治療藥物; Triple-negative breast cancer; Clinical trial; Therapeutic agent; |
中文摘要 | 三陰性乳癌 (triple-negative breast cancer, TNBC) 在組織學或基因型均具有高度異 質的特點,目前臨床尚無有效的療法及標靶藥物,也因此三陰性乳癌之治療成為現今 的研究重點。以下將介紹針對三陰性乳癌的六類藥物之臨床試驗現況,包含:含鉑 化合物 (platinum agents)、多聚二磷酸腺苷核糖聚合酶-1 (poly adenosine diphosphateribose polymerase 1, PARP1)、糖皮質激素受體拮抗劑 (glucocorticoid receptor antagonists)、雄性激素受體拮抗劑 (androgen receptor antagonists)、免疫檢查點抑制劑 (immune checkpoint inhibitors)、抗體藥物共價複合體 (antibody drug conjugates)。其中 不乏極具進行二、三期臨床試驗潛力之藥物,更有接近上市的藥物,相信距離治療三 陰性乳癌之重大突破已為期不遠。 |
英文摘要 | Triple-negative breast cancer (TNBC) is a disease with heterogeneous characteristics in histology and gene-expression. The lack of ER, PR, and HER2 receptors expression makes the definition of triple-negative, which suggests no targeted therapy available for the TNBC treatment. Furthermore, it is the poor prognosis of patients with TNBC that fosters thriving investigations into this disease in these years. Recent clinical trial results with respect to the six categories of drugs are discussed in this article. Among the drug candidates showing promising results, one even received breakthrough therapy designation from the FDA. With the vigorous researches in TNBC, this unmet clinical need may be expected to be fulfilled soon. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。